Wordt geladen...
Biomarker Development in the Context of Urologic Cancers
The FDA has called for the use of analytically validated biomarkers that have strong evidence of being fit for purpose to identify patients likely to respond and to evaluate the patient response to a therapy, potential toxicity, and drug resistance. This article discusses development and application...
Bewaard in:
| Gepubliceerd in: | Urol Oncol |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4521394/ https://ncbi.nlm.nih.gov/pubmed/25746942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2015.01.007 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|